Madison Shoaf

Journal Article Cancers · February 1, 2025 Introduction: Treatment for primary central nervous system lymphoma (PCNSL) includes high-dose methotrexate (HD-MTX)-based systemic therapy. Multiple regimens exist with no clear standard of care. We evaluated the impact of different therapies on PCNSL out ... Full text Cite

Patterns of Treatment Failure in Primary Central Nervous System Lymphoma.

Journal Article Am J Clin Oncol · July 1, 2024 OBJECTIVES: Progression of PCNSL remains a challenge with salvage therapies, including the risk of substantial morbidity and mortality. We report patterns of first tumor progression to inform opportunities for improvement. METHODS: This is an institutional ... Full text Link to item Cite

Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015-2019.

Journal Article Neurooncol Pract · February 2024 BACKGROUND: The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest aggregation of histopathology-specific population-bas ... Full text Link to item Cite

National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.

Journal Article Neuro Oncol · April 6, 2023 BACKGROUND: Molecularly-defined diffuse glioma types-including IDH-wildtype glioblastoma, IDH-mutant astrocytoma, IDH-mutant 1p/19q-codeleted oligodendroglioma, and H3 K27M-mutant diffuse midline glioma-were incorporated into U.S. cancer registry reporting ... Full text Link to item Cite

Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.

Journal Article Neurotherapeutics · October 2022 Glioblastoma is the most common primary malignant brain tumor in adults and outcomes remain poor despite the current standard of care multimodal therapy. Oncolytic virotherapy utilizes engineered viruses to exert an anti-tumor effect via both direct oncoly ... Full text Link to item Cite

Behavioral Aversion to AITC Requires Both Painless and dTRPA1 in Drosophila.

Journal Article Front Neural Circuits · 2018 There has been disagreement over the functional roles of the painless gene product in the detection and subsequent behavioral aversion to the active ingredient in wasabi, allyl isothiocyanate (AITC). Originally, painless was reported to eliminate the behav ... Full text Link to item Cite